JP2022544946A5 - - Google Patents

Info

Publication number
JP2022544946A5
JP2022544946A5 JP2022509034A JP2022509034A JP2022544946A5 JP 2022544946 A5 JP2022544946 A5 JP 2022544946A5 JP 2022509034 A JP2022509034 A JP 2022509034A JP 2022509034 A JP2022509034 A JP 2022509034A JP 2022544946 A5 JP2022544946 A5 JP 2022544946A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
enantiomer
pharmaceutically acceptable
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022509034A
Other languages
English (en)
Japanese (ja)
Other versions
JP7638960B2 (ja
JP2022544946A (ja
Filing date
Publication date
Priority claimed from PCT/CN2019/100542 external-priority patent/WO2021026803A1/en
Application filed filed Critical
Publication of JP2022544946A publication Critical patent/JP2022544946A/ja
Publication of JP2022544946A5 publication Critical patent/JP2022544946A5/ja
Priority to JP2025024756A priority Critical patent/JP2025081505A/ja
Application granted granted Critical
Publication of JP7638960B2 publication Critical patent/JP7638960B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022509034A 2019-08-14 2020-08-12 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン Active JP7638960B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025024756A JP2025081505A (ja) 2019-08-14 2025-02-19 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2019/100542 WO2021026803A1 (en) 2019-08-14 2019-08-14 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CNPCT/CN2019/100542 2019-08-14
PCT/IB2020/057602 WO2021028854A1 (en) 2019-08-14 2020-08-12 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025024756A Division JP2025081505A (ja) 2019-08-14 2025-02-19 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Publications (3)

Publication Number Publication Date
JP2022544946A JP2022544946A (ja) 2022-10-24
JP2022544946A5 true JP2022544946A5 (enExample) 2023-08-21
JP7638960B2 JP7638960B2 (ja) 2025-03-04

Family

ID=72145436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509034A Active JP7638960B2 (ja) 2019-08-14 2020-08-12 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン
JP2025024756A Pending JP2025081505A (ja) 2019-08-14 2025-02-19 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025024756A Pending JP2025081505A (ja) 2019-08-14 2025-02-19 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Country Status (20)

Country Link
US (3) US11420970B1 (enExample)
EP (2) EP4013755B1 (enExample)
JP (2) JP7638960B2 (enExample)
KR (1) KR102946008B1 (enExample)
CN (1) CN114585622B (enExample)
AU (1) AU2020328919B2 (enExample)
BR (1) BR112022002520A2 (enExample)
CO (1) CO2022002804A2 (enExample)
DK (1) DK4013755T3 (enExample)
EC (1) ECSP22019360A (enExample)
ES (1) ES3023540T3 (enExample)
FI (1) FI4013755T3 (enExample)
IL (2) IL320143A (enExample)
MX (1) MX2022001784A (enExample)
MY (1) MY209614A (enExample)
PH (1) PH12022550343A1 (enExample)
PL (1) PL4013755T3 (enExample)
PT (1) PT4013755T (enExample)
WO (2) WO2021026803A1 (enExample)
ZA (1) ZA202200519B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN114981270B (zh) * 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
JP2025504379A (ja) * 2022-01-05 2025-02-12 ケイ３６・セラピューティクス・インコーポレイテッド 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用
JP2025508714A (ja) * 2022-02-16 2025-04-10 デューク ストリート バイオ リミテッド 医薬化合物
WO2023225144A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
JP2025517349A (ja) * 2022-05-18 2025-06-05 ケイ３６・セラピューティクス・インコーポレイテッド ピペリジニル－メチル－プリンアミンｄ－酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用
US20250326752A1 (en) * 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250361235A1 (en) * 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2023230038A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
CN119894513A (zh) * 2022-09-26 2025-04-25 德州大学系统董事会 作为nsd活性调节剂的杂环
WO2024073283A1 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity
CN120641105A (zh) * 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
US20250011329A1 (en) * 2023-06-21 2025-01-09 K36 Therapeutics, Inc. Substituted piperidinyl-methylpurine pyridines and related compounds and their use in treating diseases and conditions
AU2024381513A1 (en) * 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117720550A (zh) * 2023-12-14 2024-03-19 深圳市华先医药科技有限公司 (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
IL330390A (en) * 2024-01-02 2026-08-01 K36 Therapeutics Inc Methods and medicinal compounds inhibiting NSD2 for the treatment of cancers from the piperidinyl-methyl-purinamine family
CN118459395A (zh) * 2024-05-10 2024-08-09 南通大学 一种5-(叔丁氧羰基氨基)哌啶-3-羧酸甲酯的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CA2497765A1 (en) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
JP2004137157A (ja) * 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
BR112012009329A2 (pt) * 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2019196918A1 (zh) 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
CN109223794B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN108853110B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
JP2025504379A (ja) 2022-01-05 2025-02-12 ケイ３６・セラピューティクス・インコーポレイテッド 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
JP2025517349A (ja) 2022-05-18 2025-06-05 ケイ３６・セラピューティクス・インコーポレイテッド ピペリジニル－メチル－プリンアミンｄ－酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Similar Documents

Publication Publication Date Title
JP7536761B2 (ja) 抗ウイルス剤としての官能化複素環
US20250122222A1 (en) Heterocyclic compounds and methods of use
ES2648876T3 (es) Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo
CN104119350B (zh) 氨基喹唑啉类衍生物及其盐和使用方法
JP2021502356A5 (enExample)
CN104211692B (zh) 作为欧若拉激酶抑制剂的衍生物
RU2478636C2 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДИН-2-ОНА, ОБЛАДАЮЩИЕ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ
US9453007B2 (en) Hepatitis C inhibitors and uses thereof
CN112204027A (zh) Erk 抑制剂及其应用
KR20190080897A (ko) 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
JP2017125037A (ja) イミダゾピロリジノン化合物
ME02202B (me) Jedinjenja pirolopirimidina kao inhibitori cdk4/6
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
JP2012528828A5 (enExample)
JP2012525430A5 (enExample)
JP2014530238A5 (enExample)
RU2014119250A (ru) Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака и иммунных и аутоиммунных заболеваний
JP2009539878A5 (enExample)
JP2016523974A5 (enExample)
PT2758401T (pt) Imidazopiridazinas amino-substituídas
RU2017121278A (ru) Триазоло-пиразинильные производные, применимые в качестве растворимых активаторов гуанилатциклазы
JP2018515525A5 (enExample)
CA2571627A1 (en) Substituted aryl-amine derivatives and methods of use
JP2017523223A5 (enExample)
WO2023154426A1 (en) Cdk inhibitors and methods of use thereof